Novel Therapies Boosting T Cell Immunity in Epstein Barr Virus-Associated Nasopharyngeal Carcinoma
International audience Nasopharyngeal carcinoma (NPC) is a malignant tumour of the head and neck affecting localised regions of the world, with the highest rates described in Southeast Asia, Northern Africa, and Greenland. Its high morbidity rate is linked to both late-stage diagnosis and unresponsi...
Published in: | International Journal of Molecular Sciences |
---|---|
Main Authors: | , , , , |
Other Authors: | , , , , , , |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
HAL CCSD
2020
|
Subjects: | |
Online Access: | https://hal.science/hal-02875212 https://hal.science/hal-02875212v2/document https://hal.science/hal-02875212v2/file/Novel%20Therapies%20Boosting%20T%20Cell%20Immunity%20in%20Epstein%20Barr%20Virus-Associated%20Nasopharyngeal%20Carcinoma%20%281%29.pdf https://doi.org/10.3390/ijms21124292 |
id |
ftunivlille:oai:HAL:hal-02875212v2 |
---|---|
record_format |
openpolar |
spelling |
ftunivlille:oai:HAL:hal-02875212v2 2024-06-23T07:53:22+00:00 Novel Therapies Boosting T Cell Immunity in Epstein Barr Virus-Associated Nasopharyngeal Carcinoma Renaud, Sarah Lefebvre, Anthony Mordon, Serge Morales, Olivier Delhem, Nadira Thérapies Assistées par Lasers et Immunothérapies pour l'Oncologie - U 1189 (OncoThAI) Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille) Institut de biologie de Lille - UMS 3702 (IBL) Institut Pasteur de Lille Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Université de Lille-Centre National de la Recherche Scientifique (CNRS) Institut National de la Santé et de la Recherche Médicale (INSERM) Université de Lille 2020 https://hal.science/hal-02875212 https://hal.science/hal-02875212v2/document https://hal.science/hal-02875212v2/file/Novel%20Therapies%20Boosting%20T%20Cell%20Immunity%20in%20Epstein%20Barr%20Virus-Associated%20Nasopharyngeal%20Carcinoma%20%281%29.pdf https://doi.org/10.3390/ijms21124292 en eng HAL CCSD MDPI info:eu-repo/semantics/altIdentifier/doi/10.3390/ijms21124292 hal-02875212 https://hal.science/hal-02875212 https://hal.science/hal-02875212v2/document https://hal.science/hal-02875212v2/file/Novel%20Therapies%20Boosting%20T%20Cell%20Immunity%20in%20Epstein%20Barr%20Virus-Associated%20Nasopharyngeal%20Carcinoma%20%281%29.pdf doi:10.3390/ijms21124292 info:eu-repo/semantics/OpenAccess ISSN: 1661-6596 EISSN: 1422-0067 International Journal of Molecular Sciences https://hal.science/hal-02875212 International Journal of Molecular Sciences, 2020, 21 (12), pp.4292. ⟨10.3390/ijms21124292⟩ therapy T cell immunity EBV nasopharyngeal carcinoma [SDV.CAN]Life Sciences [q-bio]/Cancer [SDV.IMM.IMM]Life Sciences [q-bio]/Immunology/Immunotherapy info:eu-repo/semantics/article Journal articles 2020 ftunivlille https://doi.org/10.3390/ijms21124292 2024-06-10T15:02:00Z International audience Nasopharyngeal carcinoma (NPC) is a malignant tumour of the head and neck affecting localised regions of the world, with the highest rates described in Southeast Asia, Northern Africa, and Greenland. Its high morbidity rate is linked to both late-stage diagnosis and unresponsiveness to conventional anti-cancer treatments. Multiple aetiological factors have been described including environmental factors, genetics, and viral factors (Epstein Barr Virus, EBV), making NPC treatment that much more complex. The most common forms of NPCs are those that originate from the epithelial tissue lining the nasopharynx and are often linked to EBV infection. Indeed, they represent 75-95% of NPCs in the low-risk populations and almost 100% of NPCs in high-risk populations. Although conventional surgery has been improved with nasopharyngectomy's being carried out using more sophisticated surgical equipment for better tumour resection, recent findings in the tumour microenvironment have led to novel treatment options including immunotherapies and photodynamic therapy, able to target the tumour and improve the immune system. This review provides an update on the disease's aetiology and the future of NPC treatments with a focus on therapies activating T cell immunity. Article in Journal/Newspaper Greenland LillOA (HAL Lille Open Archive, Université de Lille) Greenland International Journal of Molecular Sciences 21 12 4292 |
institution |
Open Polar |
collection |
LillOA (HAL Lille Open Archive, Université de Lille) |
op_collection_id |
ftunivlille |
language |
English |
topic |
therapy T cell immunity EBV nasopharyngeal carcinoma [SDV.CAN]Life Sciences [q-bio]/Cancer [SDV.IMM.IMM]Life Sciences [q-bio]/Immunology/Immunotherapy |
spellingShingle |
therapy T cell immunity EBV nasopharyngeal carcinoma [SDV.CAN]Life Sciences [q-bio]/Cancer [SDV.IMM.IMM]Life Sciences [q-bio]/Immunology/Immunotherapy Renaud, Sarah Lefebvre, Anthony Mordon, Serge Morales, Olivier Delhem, Nadira Novel Therapies Boosting T Cell Immunity in Epstein Barr Virus-Associated Nasopharyngeal Carcinoma |
topic_facet |
therapy T cell immunity EBV nasopharyngeal carcinoma [SDV.CAN]Life Sciences [q-bio]/Cancer [SDV.IMM.IMM]Life Sciences [q-bio]/Immunology/Immunotherapy |
description |
International audience Nasopharyngeal carcinoma (NPC) is a malignant tumour of the head and neck affecting localised regions of the world, with the highest rates described in Southeast Asia, Northern Africa, and Greenland. Its high morbidity rate is linked to both late-stage diagnosis and unresponsiveness to conventional anti-cancer treatments. Multiple aetiological factors have been described including environmental factors, genetics, and viral factors (Epstein Barr Virus, EBV), making NPC treatment that much more complex. The most common forms of NPCs are those that originate from the epithelial tissue lining the nasopharynx and are often linked to EBV infection. Indeed, they represent 75-95% of NPCs in the low-risk populations and almost 100% of NPCs in high-risk populations. Although conventional surgery has been improved with nasopharyngectomy's being carried out using more sophisticated surgical equipment for better tumour resection, recent findings in the tumour microenvironment have led to novel treatment options including immunotherapies and photodynamic therapy, able to target the tumour and improve the immune system. This review provides an update on the disease's aetiology and the future of NPC treatments with a focus on therapies activating T cell immunity. |
author2 |
Thérapies Assistées par Lasers et Immunothérapies pour l'Oncologie - U 1189 (OncoThAI) Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille) Institut de biologie de Lille - UMS 3702 (IBL) Institut Pasteur de Lille Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Université de Lille-Centre National de la Recherche Scientifique (CNRS) Institut National de la Santé et de la Recherche Médicale (INSERM) Université de Lille |
format |
Article in Journal/Newspaper |
author |
Renaud, Sarah Lefebvre, Anthony Mordon, Serge Morales, Olivier Delhem, Nadira |
author_facet |
Renaud, Sarah Lefebvre, Anthony Mordon, Serge Morales, Olivier Delhem, Nadira |
author_sort |
Renaud, Sarah |
title |
Novel Therapies Boosting T Cell Immunity in Epstein Barr Virus-Associated Nasopharyngeal Carcinoma |
title_short |
Novel Therapies Boosting T Cell Immunity in Epstein Barr Virus-Associated Nasopharyngeal Carcinoma |
title_full |
Novel Therapies Boosting T Cell Immunity in Epstein Barr Virus-Associated Nasopharyngeal Carcinoma |
title_fullStr |
Novel Therapies Boosting T Cell Immunity in Epstein Barr Virus-Associated Nasopharyngeal Carcinoma |
title_full_unstemmed |
Novel Therapies Boosting T Cell Immunity in Epstein Barr Virus-Associated Nasopharyngeal Carcinoma |
title_sort |
novel therapies boosting t cell immunity in epstein barr virus-associated nasopharyngeal carcinoma |
publisher |
HAL CCSD |
publishDate |
2020 |
url |
https://hal.science/hal-02875212 https://hal.science/hal-02875212v2/document https://hal.science/hal-02875212v2/file/Novel%20Therapies%20Boosting%20T%20Cell%20Immunity%20in%20Epstein%20Barr%20Virus-Associated%20Nasopharyngeal%20Carcinoma%20%281%29.pdf https://doi.org/10.3390/ijms21124292 |
geographic |
Greenland |
geographic_facet |
Greenland |
genre |
Greenland |
genre_facet |
Greenland |
op_source |
ISSN: 1661-6596 EISSN: 1422-0067 International Journal of Molecular Sciences https://hal.science/hal-02875212 International Journal of Molecular Sciences, 2020, 21 (12), pp.4292. ⟨10.3390/ijms21124292⟩ |
op_relation |
info:eu-repo/semantics/altIdentifier/doi/10.3390/ijms21124292 hal-02875212 https://hal.science/hal-02875212 https://hal.science/hal-02875212v2/document https://hal.science/hal-02875212v2/file/Novel%20Therapies%20Boosting%20T%20Cell%20Immunity%20in%20Epstein%20Barr%20Virus-Associated%20Nasopharyngeal%20Carcinoma%20%281%29.pdf doi:10.3390/ijms21124292 |
op_rights |
info:eu-repo/semantics/OpenAccess |
op_doi |
https://doi.org/10.3390/ijms21124292 |
container_title |
International Journal of Molecular Sciences |
container_volume |
21 |
container_issue |
12 |
container_start_page |
4292 |
_version_ |
1802644966138183680 |